Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 18/20 | 0.93 |
| ▸ | ESR2 known ✓ | Q92731 | 16/20 | 0.93 |
| ▸ | MEN1 | O00255 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | TP53 | P04637 | 2/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.93 |
| ▸ | MAPT | P10636 | 2/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.93 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.93 |
| ▸ | PLD2 | O14939 | 1/20 | 0.93 |
| ▸ | KDM1A | O60341 | 1/20 | 0.93 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.93 |
| ▸ | USP2 | O75604 | 1/20 | 0.93 |
| ▸ | C5 | P01031 | 1/20 | 0.93 |
| ▸ | FYN | P06241 | 1/20 | 0.93 |
| ▸ | PGR | P06401 | 1/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene SCHEMBL2234855 | 0.96 | ESR1 (0.90) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL2733917 | 0.96 | ESR1 (0.90) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL29362592 | 0.96 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL6144 | 0.96 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 0.96 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL3162158 | 0.96 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL5821250 | 0.96 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL976686 | 0.96 | ESR1 (0.85) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL2235454 | 0.96 | ESR1 (0.88) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL2235455 | 0.96 | ESR1 (0.88) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1832583-A1 | Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these | A/S GEA Farmaceutisk Fabrik (DK) | 2007-09-12 | — | — | EP | claimed |
| US-7964734-B2 | Raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these | A/S GEA FARMACEUTISK FABRIK (DK) | 2011-06-21 | — | — | US | disclosed |
| EP-1832583-A1 | Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these | A/S GEA Farmaceutisk Fabrik (DK) | 2007-09-12 | — | — | EP | disclosed |
| EP-1832582-A1 | Novel raloxifene malonic acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these | A/S GEA Farmaceutisk Fabrik (DK) | 2007-09-12 | — | — | EP | disclosed |
| EP-1832583-A1 | Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these | A/S GEA Farmaceutisk Fabrik (DK) | 2007-09-12 | — | — | EP | disclosed |
| EP-1832583-A1 | Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these | A/S GEA Farmaceutisk Fabrik (DK) | 2007-09-12 | — | — | EP | disclosed |
| EP-1826205-A1 | Novel raloxifene succinic acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these | A/S GEA Farmaceutisk Fabrik (DK) | 2007-08-29 | — | — | EP | disclosed |
| US-20060154966-A1 | Novel raloxifene acid additon salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these | A/S GEA FARMACEUTISK FABRIK (DK) | 2006-07-13 | — | — | US | disclosed |
| EP-1546138-A2 | NOVEL RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF, IMPROVED METHOD FOR PURIFICATION OF SAID RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE | A/S GEA Farmaceutisk Fabrik (DK) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029046-A2 | NOVEL RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF, IMPROVED METHOD FOR PURIFICATION OF SAID RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE | A/S GEA FARMACEUTISK FABRIK (DK) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154966-A1 | Novel raloxifene acid additon salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these | SI, SUCNR1, LDHA | ESR1 86/4885ESR2 188/4885MEN1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.